Stryker to market LifeCell's tissue-based bone graft:
This article was originally published in Clinica
Executive Summary
Stryker Howmedica Osteonics is to be the exclusive marketer of the bone-grafting product currently being developed by LifeCell (Branchburg, New Jersey). The product combines its tissue processing technology and demineralised bone matrix. LifeCell expects the product to be launched by the end of 2003. Under the 10-year deal, Stryker will be responsible for marketing and LifeCell for development, tissue processing and distribution
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.